- Home
- CLLS vs VNDA Comparison
CLLS vs VNDA Comparison
Compare CLLS & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CLLS | VNDA |
|---|---|---|
| Founded | 1999 | 2002 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 299.0M | 289.0M |
| IPO Year | 2007 | 2006 |
Fundamental Metrics
Financial Performance| Metric | CLLS | VNDA |
|---|---|---|
| Price | $4.39 | $6.76 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $8.00 | ★ $14.00 |
| AVG Volume (30 Days) | 132.4K | ★ 1.2M |
| Earning Date | 11-07-2025 | 10-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $82,551,000.00 | ★ $212,074,000.00 |
| Revenue This Year | $32.58 | $12.01 |
| Revenue Next Year | N/A | $21.57 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 129.04 | 11.12 |
| 52 Week Low | $1.10 | $3.81 |
| 52 Week High | $5.48 | $7.05 |
Technical Indicators
Market Signals| Indicator | CLLS | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 49.34 | 66.88 |
| Support Level | $4.47 | $6.15 |
| Resistance Level | $5.45 | $7.05 |
| Average True Range (ATR) | 0.30 | 0.45 |
| MACD | -0.12 | 0.09 |
| Stochastic Oscillator | 31.17 | 86.57 |
Price Performance
Historical ComparisonAbout CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.